

1 MAYER BROWN LLP
DALE J. GIALI (SBN 150382)
2 *dgiali@mayerbrown.com*
KERI E. BORDERS (SBN 194015)
3 *kborders@mayerbrown.com*
350 South Grand Avenue, 25th Floor
4 Los Angeles, CA 90071-1503
Telephone: (213) 229-9500
5 Facsimile: (213) 625-0248

6 DECHERT LLP
Hope Freiwald (admitted *pro hac vice*)
7 *hope.freiwald@dechert.com*
2929 Arch Street,
8 Philadelphia, PA 19104-2808
Telephone: (215) 994-4000
9 Facsimile: (215) 994-2222

10 Mark Cheffo (admitted *pro hac vice*)
11 *mark.cheffo@dechert.com*
1095 Avenue of the Americas,
12 New York, NY, 10036-6797
Telephone: (212) 698-3500
13 Facsimile: (212) 994-3599

14 Attorneys for Defendant
15 Plum, PBC

16 **UNITED STATES DISTRICT COURT**
17 **NORTHERN DISTRICT OF CALIFORNIA, OAKLAND DIVISION**

18 **IN RE PLUM BABY FOOD LITIGATION**

19
20 This Document Relates To: All Actions

Master File No. 4:21-cv-00913-YGR

Hon: Yvonne Gonzalez Rogers

**DEFENDANT PLUM, PBC'S NOTICE OF
MOTION AND MOTION TO DISMISS,
OR IN THE ALTERNATIVE, TO STAY;
MEMORANDUM OF POINTS AND
AUTHORITIES IN SUPPORT THEREOF**

Date: January 11, 2022

Time: 2:00 p.m.

Courtroom: 1

*[Declaration of Keri E. Borders and
[Proposed] Order Filed Concurrently
Herewith]*

TO ALL PARTIES AND THEIR ATTORNEYS OF RECORD:

PLEASE TAKE NOTICE that on January 11, 2022, at 2:00 p.m., or as soon thereafter as the matter may be heard, in Courtroom 1, 4th Floor, of this Court, located at 1301 Clay Street, Oakland, CA 94612, before the Honorable Yvonne Gonzalez Rogers, defendant Plum, PBC (also erroneously sued as Plum, Inc.¹) (collectively, “Plum”) will and hereby does move the Court for an order dismissing the first amended consolidated class action complaint (“FACC”), and each claim contained therein, with prejudice, or in the alternative, staying this action.

This motion is made pursuant to Fed. R. Civ. P. 8, 12(b)(1), and 12(b)(6), and is based on the following grounds:

1. Plaintiffs lack Article III standing to pursue their claims and to seek injunctive relief;
2. Plaintiffs’ state law claims are barred by the doctrine of conflict preemption;
3. The Court should dismiss/stay this case in deference to FDA’s primary jurisdiction;
4. Plaintiffs do not plausibly allege that they were, or that reasonable consumers would be, deceived by the challenged statements and omissions in the manner alleged; and
5. Plaintiffs’ claims for breach of implied warranty fail for the additional reason that plaintiffs cannot allege that the challenged products were not fit for their ordinary purpose.

The motion is supported by this notice, the attached memorandum of points and authorities, the declaration of Keri E. Borders, pleadings and documents on file in this case, and on such other written and oral argument as may be presented to the Court on this matter motion.

Dated: October 18, 2021

MAYER BROWN LLP
Dale J. Giali
Keri E. Borders

DECHERT LLP
Hope Freiwald (admitted *pro hac vice*)
Mark Cheffo (admitted *pro hac vice*)

by: /s/ Keri E. Borders
Keri E. Borders
Attorneys for Defendant PLUM, PBC

¹ In 2013, Plum, Inc. was converted into a public benefit corporation and was renamed Plum, PBC. Accordingly, Plum, Inc. no longer exists.

TABLE OF CONTENTS

		Page(s)
1		
2		
3		
4	STATEMENT OF ISSUES TO BE DECIDED	1
5	I. INTRODUCTION	1
6	II. FACTUAL BACKGROUND	3
7	A. FDA Is Responsible For Regulating Food Safety, Including Heavy Metals,	
8	In The U.S. Food Supply	3
9	B. FDA’s “Closer To Zero: Action Plan For Baby Foods”	5
10	III. ARGUMENT	6
11	A. Plaintiffs Lack Standing To Pursue Their Claims	6
12	1. Plaintiffs Have Not Pleaded That They Suffered An Injury In Fact.....	6
13	2. Plaintiffs Lack Standing To Seek Injunctive Relief	10
14	B. Plaintiffs’ Claims Should Be Dismissed As Preempted	11
15	C. Plaintiffs’ Claims Fall Under FDA’s Primary Jurisdiction.....	15
16	D. Plaintiffs Fail To Plausibly Allege Deception	19
17	E. Plaintiffs’ Breach Of Implied Warranty Claim Fails	23
18	F. Request For Judicial Notice	24
19	IV. CONCLUSION	25
20		
21		
22		
23		
24		
25		
26		
27		
28		

TABLE OF AUTHORITIES**Page(s)****Cases**

<i>All. for Bio-Integrity v. Shalala,</i> 116 F. Supp. 2d 166 (D.D.C. 2000)	4
<i>Allen v. Hyland's Inc.,</i> 300 F.R.D. 643 (C.D. Cal. 2014)	8
<i>In re Apple Processor Litig.,</i> 2019 WL 3533876 (N.D. Cal. Aug. 2, 2019)	7
<i>Arent v. Shalala,</i> 70 F.3d 610 (D.C. Cir. 1995)	4
<i>Arizona v. United States,</i> 567 U.S. 387 (2012)	12
<i>Astiana v. Hain Celestial Grp., Inc.,</i> 783 F.3d 753 (9th Cir. 2015)	15, 16
<i>Axon v. Citrus World, Inc.,</i> 354 F. Supp. 3d 170 (E.D.N.Y. 2018)	23
<i>Axon v. Florida's Nat. Growers, Inc.,</i> 813 F. App'x 701 (2d Cir. 2020)	23
<i>Backus v. Gen. Mills, Inc.,</i> 122 F. Supp. 3d 909 (N.D. Cal. 2015)	15, 16, 17, 18
<i>Backus v. Nestlé USA, Inc.,</i> 167 F. Supp. 3d 1068 (N.D. Cal. 2016)	12
<i>Barreto v. Westbrae Nat.,</i> 2021 WL 76331 (S.D.N.Y. Jan. 7, 2021)	23, 24
<i>Bohac v. Gen. Mills, Inc.,</i> 2014 WL 1266848 (N.D. Cal. Mar. 26, 2014)	24
<i>Boysen v. Walgreen Co.,</i> 2012 WL 2953069 (N.D. Cal. July 19, 2012)	9
<i>Brazil v. Dole Packaged Foods LLC,</i> 660 F. App'x 531 (9th Cir. 2016)	8
<i>Busey v. P.W. Supermarkets, Inc.,</i> 368 F. Supp. 2d 1045 (N.D. Cal. 2005)	24

1	<i>Cimoli v. Alacer Corp.</i> ,	
2	--- F. Supp. 3d ----, 2021 WL 2711770 (N.D. Cal. July 1, 2021)	11
3	<i>City of L.A. v. Lyons</i> ,	
4	461 U.S. 95 (1983)	10
5	<i>Clark v. Time Warner Cable</i> ,	
6	523 F.3d 1110 (9th Cir.2008)	15, 18
7	<i>Cohen v. Apple, Inc.</i>	
8	497 F. Supp. 3d 769 (N.D. Cal. 2020)	12
9	<i>Colette v. CV Scis., Inc.</i> ,	
10	2020 WL 2739861 (C.D. Cal. May 22, 2020)	16
11	<i>Daigle v. Ford Motor Co.</i> ,	
12	713 F. Supp. 2d 822 (D. Minn. 2010)	24
13	<i>Davidson v. Kimberly-Clark Corp.</i> ,	
14	889 F.3d 956 (9th Cir. 2018)	10
15	<i>Dennis v. Whirlpool Corp.</i> ,	
16	2007 WL 9701826 (S.D. Fla. Mar. 13, 2007)	24
17	<i>Doss v. Gen. Mills, Inc.</i> ,	
18	816 F. App'x 312 (11th Cir. 2020)	9
19	<i>Farina v. Nokia Inc.</i> ,	
20	625 F.3d 97 (3d Cir. 2010)	13, 14
21	<i>Fid. Fed. Sav. & Loan Ass'n v. de la Cuesta</i> ,	
22	458 U.S. 141 (1982)	12
23	<i>Gaminde v. Lang Pharma Nutrition, Inc.</i> ,	
24	2019 WL 1338724 (N.D.N.Y. Mar. 25, 2019)	7
25	<i>Geier v. Am. Honda Motor Co.</i> ,	
26	529 U.S. 861 (2000)	12
27	<i>In re Gen. Mills Glyphosate Litig.</i> ,	
28	2017 WL 2983877 (D. Minn. July 12, 2017)	23
	<i>Gibson v. Quaker Oats Co.</i> ,	
	2017 WL 3508724 (N.D. Ill. Aug. 14, 2017)	23
	<i>Glass v. Glob. Widget, LLC</i> ,	
	2020 WL 3174688 (E.D. Cal. June 15, 2020)	16
	<i>Green v. PepsiCo, Inc.</i> ,	
	2019 WL 8810364 (S.D. Fla. Apr. 12, 2019)	9

1	<i>Hauter v. Zogarts</i> ,	
2	14 Cal. 3d 104 (1975)	23
3	<i>Hawkins v. Advancepierre Foods, Inc.</i> ,	
4	2016 WL 6611099 (S.D. Cal. Nov. 8, 2016)	17
5	<i>Herrington v. Johnson & Johnson Consumer Companies</i> ,	
6	2010 WL 3448531 (N.D. Cal. Sept. 1, 2010)	8, 22
7	<i>Jackson v. Gen. Mills, Inc.</i> ,	
8	2020 WL 5106652 (S.D. Cal. Aug. 28, 2020)	11
9	<i>Joslin v. Clif Bar & Co.</i> ,	
10	2019 WL 5690632 (N.D. Cal. Aug. 26, 2019)	11
11	<i>Kane v. Chobani, LLC</i> ,	
12	645 F. App'x 593 (9th Cir. 2016)	16
13	<i>In re KIND LLC "Healthy & All Natural" Litig.</i> ,	
14	209 F. Supp. 3d 689 (S.D.N.Y. 2016).....	17, 19
15	<i>Koronthaly v. L'Oreal USA, Inc.</i> ,	
16	2008 WL 2938045 (D.N.J. July 29, 2008).....	9
17	<i>Lanovaz v. Twinings N. Am., Inc.</i> ,	
18	726 F. App'x 590 (9th Cir. 2018)	11
19	<i>Maryland v. Louisiana</i> ,	
20	451 U.S. 725 (1981).....	12
21	<i>McGee v. S-L Snacks Nat'l</i> ,	
22	982 F.3d 700 (9th Cir. 2020)	6, 9, 22
23	<i>Moore v. Trader Joe's Co.</i> ,	
24	4 F.4th 874 (9th Cir. 2021)	22
25	<i>Moreno v. Vi-Jon, Inc.</i> ,	
26	2021 WL 807683 (S.D. Cal. March 3, 2021).....	9
27	<i>Parks v. Ainsworth Pet Nutrition, LLC</i> ,	
28	2020 WL 832863 (S.D.N.Y. Feb. 20, 2020).....	22
	<i>Parks v. Ainsworth Pet Nutrition, LLC</i> ,	
	377 F. Supp. 3d 241 (S.D.N.Y. 2020).....	22
	<i>In re Pom Wonderful LLC</i> ,	
	2014 WL 1225184 (C.D. Cal. Mar. 25, 2014).....	8
	<i>Rahman v. Mott's LLP</i> ,	
	2018 WL 4585024 (N.D. Cal. Sept. 25, 2018)	11

1	<i>Reese v. Odwalla, Inc.</i> ,	
2	30 F. Supp. 3d 935 (N.D. Cal. 2014)	16, 17
3	<i>Riva v. Pepsico, Inc.</i> ,	
4	2015 WL 993350 (N.D. Cal. Mar. 4, 2015).....	25
5	<i>Rosillo v. Annie's Homegrown Inc.</i> ,	
6	2017 WL 5256345 (N.D. Cal. Oct. 17, 2017).....	16
7	<i>Salmon Spawning & Recovery All. v. Gutierrez</i> ,	
8	545 F.3d 1220 (9th Cir. 2008)	6
9	<i>Sportmart, Inc. v. Spirit Mfg.</i> ,	
10	1999 WL 350662 (N.D. Ill. May 17, 1999)	23
11	<i>Stearns v. Select Comfort Retail Corp.</i> ,	
12	2009 WL 1635931 (N.D. Cal. June 5, 2009)	24
13	<i>Stover v. Experian Holdings, Inc.</i> ,	
14	978 F.3d 1082 (9th Cir. 2020)	10
15	<i>Syntek Semiconductor Co. v. Microchip Tech.</i> ,	
16	307 F.3d 775 (9th Cir. 2002)	16
17	<i>Takeda Pharms. U.S.A., Inc. v. Burwell</i> ,	
18	691 F. App'x 634 (D.C. Cir. 2016).....	4
19	<i>Thomas v. Costco Wholesale Corp.</i> ,	
20	2014 WL 5872808 (N.D. Cal. Nov. 12, 2014)	24
21	<i>Ting v. AT&T</i> ,	
22	319 F.3d 1126 (9th Cir. 2003)	12
23	<i>In re Tobacco Cases II</i> ,	
24	240 Cal. App. 4th 779 (2015)	8
25	<i>Tran v. Sioux Honey Ass'n</i> ,	
26	2017 WL 5587276 (C.D. Cal. Oct. 11, 2017).....	16, 18
27	<i>Tran v. Sioux Honey Ass'n</i> ,	
28	2020 WL 3989444 (C.D. Cal. July 13, 2020).....	23
	<i>Viggiano v. Hansen Nat. Corp.</i> ,	
	944 F. Supp. 2d 877 (C.D. Cal. 2013)	24
	<i>Wilson v. Frito-Lay N. Am., Inc.</i> ,	
	260 F. Supp. 3d 1202 (N.D. Cal. 2017)	25
	<i>Yu v. Dr Pepper Snapple Grp.</i> ,	
	2019 WL 2515919 (N.D. Cal. June 18, 2019).....	23

Statutes

21 U.S.C. § 331.....	4
21 U.S.C. § 341.....	17
21 U.S.C. § 342.....	4, 14
21 U.S.C. § 346.....	14, 17
21 U.S.C. § 343-1	16
21 U.S.C. § 371.....	3
21 U.S.C. § 393.....	3
21 U.S.C. § 350l.....	4

Regulations

21 C.F.R. § 7.1	3
21 C.F.R. § 10.30.....	4
21 C.F.R. § 165.110.....	14

Rules

Fed. R. Evid. 201	25
-------------------------	----

Constitution Articles

U.S. CONST. art. VI, cl. 2	12
----------------------------------	----

STATEMENT OF ISSUES TO BE DECIDED

1. Do plaintiffs have Article III standing to pursue their claims?
2. Are plaintiffs’ state-law claims preempted?
3. Should plaintiffs’ claims be dismissed (or stayed) pursuant to the primary jurisdiction doctrine?
4. Have plaintiffs plausibly alleged that they were deceived by Plum’s labels?
5. Have plaintiffs adequately alleged a claim for breach of implied warranty?

I. INTRODUCTION

Because plaintiffs have not alleged a cognizable injury—and separately because this false advertising consumer class action is an implausible and improper attempt to appropriate the mandate of the Food & Drug Administration (“FDA”) to develop and implement national food safety and labeling policy—the first amended consolidated complaint (“FACC”) should be dismissed or, at a minimum, stayed on numerous independent grounds.

Plaintiffs sue on behalf of a putative class of purchasers of baby food products sold under the “Plum Organics” brand, alleging that they were deceived because Plum labeling did not disclose that low levels of certain heavy metals *may* exist in those products as a result of their ingredients. Plaintiffs’ lawsuit follows on the heels of a February 4, 2021 staff report issued by the Subcommittee on Economic and Consumer Policy of the U.S. House of Representatives’ Committee regarding heavy metals in baby food (the “Subcommittee Report”). The Subcommittee Report claimed to follow an “investigation” into the presence of naturally occurring trace amounts of heavy metals in the fruits, vegetables and rice in baby food—the same trace heavy metals levels ubiquitous in all such fruits, vegetables and rice in the U.S. food supply—and raised alarm that baby food products sold by virtually all manufacturers might be “unsafe.” The immediate fear caused to caretakers was as needless as it was expected. The Subcommittee Report relied heavily on a report previously issued by a consumer advocacy group, whose methods and conclusions have never been peer reviewed or tested. Moreover, the Subcommittee Report was the work product of politicians and their staff, not qualified scientists. Notably, the Subcommittee Report called on FDA—the agency charged with authority to ensure

1 the safety of the U.S. food supply and to regulate food products—to take specific actions related
2 to testing, labeling, use and non-use of certain ingredients, and the setting of “action levels” (i.e.,
3 maximum allowable levels), where necessary, for heavy metals in baby food.

4 FDA responded quickly to the Subcommittee Report. Rather than endorsing it or the
5 Subcommittee’s recommendations, FDA expressed serious concern over politicians making
6 proposals that were not science based and that could harm children by reducing their
7 consumption of healthy and nutritious food. FDA also corrected a significant erroneous
8 implication of the Subcommittee Report, i.e., that FDA had failed to act. FDA *does* actively
9 monitor heavy metals in the food supply. Its decision not to set action levels in the past or engage
10 in other rulemaking to regulate baby food reflects the results of FDA’s active monitoring and its
11 considered judgment that such actions were not warranted or necessary. FDA made clear that its
12 “testing [. . .] shows that children are *not at an immediate health risk* from exposure to toxic
13 elements in food.” Declaration of Keri E. Borders (“Borders Decl.”), Ex. E at 3. With these and
14 other statements, FDA did what it could to reassure the public that packaged baby food has been
15 and remains safe, and should continue to feed babies and toddlers packaged baby food.

16 Nevertheless, within days of the issuance of the Subcommittee Report, consumer lawyers
17 began filing what are now 136 materially identical consumer class actions against baby food
18 manufacturers alleging that their baby food products were “falsely advertised” because the
19 product labels did not expressly “disclose” the presence of one or more of the heavy metals
20 found in almost all food.

21 Plaintiffs’ claims have no merit. FDA is on the job and has been focusing on the issues
22 addressed in the Subcommittee Report for years. As part of its past work, FDA concluded that
23 setting action levels, such as for arsenic in infant rice cereal, was appropriate², but declined to do
24 so for other baby food products. Now, FDA is formally redoubling its efforts and re-considering
25 its work. FDA has made clear that—if deemed necessary by qualified experts reviewing relevant
26

27 ² FDA also issued guidance regarding acceptable limits for lead in candy. *See*
28 <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-lead-candy-likely-be-consumed-frequently-small-children>. .

evidence, and after hearing from all stakeholders—it may adopt regulations, including action levels, regarding heavy metals in food. Consistent with its mandate, FDA will ensure that any such action will be supported by the scientific evidence. Claims in private litigation seeking to impose remedies that necessarily differ from FDA’s considered judgment—on a piecemeal case-by-case, company-by-company, product-by-product basis, no less—are barred by conflict preemption. Separately, where, as here, FDA is currently and formally continuing its review of these issues and has previewed that it will determine based on such review whether rulemaking is warranted, lawsuits overlapping with FDA’s work should be dismissed (or, at a minimum, stayed) in deference to FDA’s primary jurisdiction.

But the Court need not reach those dispositive arguments because the FACC fails at the outset to allege an injury in fact, a threshold fundamental allegation required to demonstrate Article III standing, as recently confirmed in this Circuit and elsewhere. Plaintiffs’ allegations that their purchased products *may* have contained *some* heavy metals, with no specific allegations of how these plaintiffs were, or could have been, *actually injured*, is insufficient to allege standing. Additionally, the FACC fails to state a claim because plaintiffs do not plausibly allege that they were deceived by the labeling or advertising of Plum’s baby food products, plaintiffs lack standing to assert claims for injunctive relief, and plaintiffs fail to state a claim for breach of implied warranty.

For these reasons, as set forth more fully below, the motion to dismiss the FACC should be granted.

II. FACTUAL BACKGROUND

A. FDA Is Responsible For Regulating Food Safety, Including Heavy Metals, In The U.S. Food Supply

The Food Drug & Cosmetic Act (“FDCA”) requires FDA to (i) ensure that foods are safe, wholesome, sanitary, and properly labeled, (ii) promulgate regulations to enforce the provisions of the FDCA, and (iii) enforce its regulations through administrative proceedings. 21 U.S.C. §§ 371, 393(b)(2)(A), 21 C.F.R. §§ 7.1, *et seq.*

The FDCA prohibits “[t]he introduction or delivery for introduction into interstate

1 commerce of any food . . . that is adulterated[.]” 21 U.S.C. §§ 331(a). Food is deemed to be
 2 adulterated when it fails to meet certain standards, including when it is harmful to human health.
 3 *See* 21 U.S.C. § 342. Relevant here, a food is not deemed to be adulterated because of the
 4 presence of unavoidable heavy metals or any other substance “*if the quantity of such substance*
 5 *in such food does not ordinarily render it injurious to health.*” 21 U.S.C. § 342 (emphasis
 6 added). Further, federal law requires that when such a substance cannot be avoided in food and
 7 may be present at levels that could be harmful, FDA sets action levels that may not be exceeded.
 8 21 U.S.C. § 346. The action levels reflect considered scientific judgment and decision-making
 9 about when food may be rendered unsafe by the presence of poisonous or deleterious substances.

10 All of this means that when a food contains harmful substances such that it is deemed
 11 adulterated under the law and unsafe to consume, the food is prohibited to be sold in interstate
 12 commerce. Following from this, FDA is and has been for decades well aware of heavy metals in
 13 the U.S. food supply and has been taking action it deems warranted and appropriate under the
 14 law, and declining to take action where action is unnecessary or unwarranted under the law.³

15 Thus, where an allegedly poisonous or deleterious substance is in food and cannot be
 16 avoided entirely, FDA sets limits for the contaminant that may not be exceeded. FDA has not
 17 found it warranted or necessary to set a limit for most heavy metals in baby food. Significantly,
 18 that is because FDA limits substances when it determines that the substances may be present in
 19 harmful or dangerous levels and FDA has not made that determination. Moreover, if it is
 20 determined that food is adulterated within the meaning of Section 342, FDA has the authority to
 21 order a recall of that food. 21 U.S.C. § 350l. FDA confirms this in its February 16, 2021
 22 Constituent Update, when it states that if FDA finds that the products violate the law, including

23 ³ If plaintiffs’ argument is that FDA is not following the law or meeting its obligations (and there
 24 is zero support in the FACC for that assertion), that challenge is properly brought in a citizen’s
 25 petition or a lawsuit directed at the agency itself. *See* 21 C.F.R. § 10.30; *Takeda Pharms. U.S.A.,*
 26 *Inc. v. Burwell*, 691 F. App’x 634, 636 (D.C. Cir. 2016); *Arent v. Shalala*, 70 F.3d 610, 612
 27 (D.C. Cir. 1995); *All. for Bio-Integrity v. Shalala*, 116 F. Supp. 2d 166, 170 (D.D.C. 2000).
 28 Permitting plaintiffs to use the consumer class action device against food manufacturers to raise
 grievances that, at best for plaintiffs, should be directed to FDA threatens to upend the orderly
 and uniform national standard for food regulation. It would also lead to the untenable scenario of
 companies being held liable for following FDA regulations and guidance.

1 not being safe, “the agency takes steps to stop the product from being imported, takes court
 2 action to stop its sale or recalls it if it is in the domestic market.” Borders Decl., Ex. C at 2.
 3 Again, with respect to baby food, and in direct response to the Subcommittee Report, FDA
 4 informed the public that “testing shows that children are *not at an immediate health risk* from
 5 exposure to toxic elements in foods.” Borders Decl., Ex. E at 3. FDA also assured the public that
 6 it “routinely monitors” levels of heavy metals, and if the levels pose a health risk, FDA would
 7 take steps to remove the affected foods from the market. *Id.* FDA urged consumers not to throw
 8 out or stop feeding packaged baby foods to babies and children, cautioning that eliminating food
 9 groups from children’s diets could result in nutritional deficiencies and potential poor health
 10 outcomes. *See id.* In doing so, FDA recognized that given the ubiquitous nature of heavy metals,
 11 there are limits to how low the levels in food can be, and requiring levels that are neither justified
 12 nor feasible “could result in significant reductions in the availability of nutritious, affordable
 13 foods that many families rely on for their children.” Borders Decl., Ex. J at 1.

14 **B. FDA’s “Closer To Zero: Action Plan For Baby Foods”**

15 On April 8, 2021—in direct response to the Subcommittee Report—FDA announced its
 16 “Closer to Zero: Action Plan for Baby Foods,” a comprehensive multi-year plan identifying
 17 actions FDA “will take to reduce exposure to toxic elements from foods eaten by babies and
 18 young children—to as low as possible.” Borders Decl., Ex. B at 1. Significantly, the Action Plan
 19 recognizes that “[r]educing levels of toxic elements in foods is complicated and multifaceted,”
 20 and that it is “crucial” that measures taken not have unintended harmful consequences such as
 21 eliminating from the marketplace certain foods, committing itself to a “science-driven,
 22 transparent, and inclusive process that will include active stakeholder engagement and public
 23 sharing of data and information.” *Id.* at 2.

24 The Action Plan has four specific stages: (1) evaluating the scientific basis for action
 25 levels, including establishing an interim reference level for certain toxic elements as appropriate;
 26 (2) proposing action levels for certain elements in categories of baby foods and other foods
 27
 28

commonly eaten by babies and young children; (3) consulting with stakeholders regarding proposed action levels; and (4) finalizing those levels. *Id.* at 3-4.⁴

Beginning in April 2021, FDA proposed a specific timeline for the four phases, and will “establish a timeframe for assessing industry’s progress toward meeting the action levels and recommence the cycle to determine if the scientific data supports efforts to further adjust the action levels.” *Id.* at 4. On October 8, 2021, FDA formally announced its first public meeting to receive stakeholder input on its Action Plan. Borders Decl., Ex. F.

Contrary to a specific remedy plaintiffs seek in this action, the Action Plan does not contemplate requiring warning labels or disclosures on baby food products regarding ubiquitous heavy metals in the food supply, and there is no basis to assume, let alone conclude, that the final policy decisions implemented by FDA will require manufacturers to change their labeling or advertising in any way. Regardless, like the action level determinations, labeling requirements, too, would be FDA’s decision to make.

III. ARGUMENT

A. Plaintiffs Lack Standing To Pursue Their Claims

1. Plaintiffs Have Not Pleaded That They Suffered An Injury In Fact

As a threshold dispositive matter, plaintiffs fail to allege that they suffered an injury in fact and, thus, they lack Article III standing. Specifically, plaintiffs have not (and cannot) allege that they suffered a physical or economic injury as a result of their past purchases of safe to consume baby food. To establish Article III standing, a plaintiff must show that “(1) he or she has suffered an injury in fact that is concrete and particularized, and actual or imminent; (2) the injury is fairly traceable to the challenged conduct; and (3) the injury is likely to be redressed by a favorable court decision.” *Salmon Spawning & Recovery All. v. Gutierrez*, 545 F.3d 1220, 1225 (9th Cir. 2008); *McGee v. S-L Snacks Nat’l*, 982 F.3d 700, 706 (9th Cir. 2020).

⁴ FDA defines “[a]ction levels a[s] a level of contamination at which a food may be regarded as adulterated within the meaning of section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act.” Borders Decl., Ex. E at 2.

1 Allegations of actual injury suffered by plaintiffs are nonexistent in the FACC. That
 2 makes sense given that (i) plaintiffs and their children suffered no physical injury; and (ii)
 3 plaintiffs purchased and received baby food products that their children presumably consumed.
 4 And that, in turn, makes sense given that FDA has made clear, subsequent to the Subcommittee
 5 Report, that packaged baby food is safe and consumers should *not* throw out or cease feeding
 6 their children packaged baby food. Borders Decl., Ex. D at 2.

7 What the FACC *does* allege is that plaintiffs would not have purchased Plum products⁵ if
 8 they had been aware of the presence, or risk of the presence, of heavy metals in baby food. *See*
 9 FACC ¶¶ 30, 33, 36, 39, 42, 45, 48, 51, 53, 56. Plaintiffs allege that they paid money for
 10 products that were tainted by the mere presence of heavy metals and that because of that the
 11 products were completely worthless and plaintiffs are entitled to a refund of the entire purchase
 12 price.⁶ *See e.g.*, FACC ¶ 239 (plaintiffs seek restitution “in the amount they spent on the Baby
 13 Foods”); 323 (plaintiffs seek injunctive and declaratory relief, full refund, actual and punitive
 14 damages, statutory damages, and attorneys’ fees). But as a robust body of case law clearly holds,
 15 these allegations of hypothetical economic injury do not constitute a legally cognizable injury
 16 that confers standing, where, like here, the products were not “worthless.”

17
 18 ⁵ Presumably, on this same logic, plaintiffs would not have purchased any foods containing
 19 vegetables, fruits or grains *at all*, considering all foods grown in soil, water and air may contain
 some amount of heavy metals from the environment.

20 ⁶ Plaintiffs fail to allege that the specific baby food products *they* purchased contained any of the
 21 alleged contaminants, which provides another basis to dismiss the FACC. *See, e.g., Gaminde v.*
 22 *Lang Pharma Nutrition, Inc.*, 2019 WL 1338724 (N.D.N.Y. Mar. 25, 2019) (dismissing putative
 23 action for lack of standing where there was no showing that *plaintiff* had tested the particular
 24 product *he* purchased); *In re Apple Processor Litig.*, 2019 WL 3533876, at *8 (N.D. Cal. Aug. 2,
 25 2019). Instead, plaintiffs rely on testing discussed in the Subcommittee Report conducted by
 26 third-party Healthy Babies Bright Futures for the allegation that “limited independent testing has
 27 revealed the presence of toxic heavy metals in [Plum’s] baby food,” FACC, Ex. 1 at 45, and
 28 “recent testing” of two Plum products, *id.* ¶ 19. However, these third-party sources have no
 bearing on the baby food *plaintiffs* purchased, and plaintiffs cannot save their claims with
 equivocal language that the baby food *could* have contained alleged contaminants. Moreover, the
 Subcommittee Report does not claim that all of the products discussed therein contained all of
 the challenged heavy metals at levels of concern. *See generally* FACC, Ex. 1. Rather, the
 Subcommittee Report asserts that some products may contain certain alleged contaminants at
 levels of concern, at the date of testing. *Id.*

For example, in *Herrington v. Johnson & Johnson Consumer Companies*, 2010 WL 3448531 (N.D. Cal. Sept. 1, 2010), plaintiffs argued that they pleaded an injury sufficient to confer standing because “they unknowingly purchased products containing potential carcinogens and that ‘they would have never purchased these products had they known of the presence of these contaminants.’” *Id.* at *4. The court rejected the theory on an Article III basis, reasoning that plaintiffs failed to plead “a distinct risk of harm from a defect in Defendants’ products that would make such an economic injury cognizable.” *Id.* Specifically, plaintiffs failed to plead that the challenged products were unfit for use or defective, and allegations that carcinogens had been detected in the bath products, that scientists believed there is no safe level of exposure to a carcinogen, and that children are generally more vulnerable to toxic exposure than adults were *not* sufficient to show a palpable risk. *Id.* at *3 (“[plaintiffs] only allege that 1,4–dioxane and formaldehyde *may* be carcinogenic for humans, that there *could* be no safe levels for exposure to carcinogens and that Defendants’ products contain some amount of these substances.”).

Plaintiffs’ allegations are no better than those rejected in *Herrington*. Plaintiffs do not allege (because they can’t) that any of the baby food products they purchased contained levels of heavy metals that rendered them unsafe to consume or devoid of nutrition and were, therefore, worthless. That tracks with the FDA’s clear pronouncements repeated in this motion: these products are not harmful, are safe to consume, and parents and caregivers should continue to serve them. *See Allen v. Hyland’s Inc.*, 300 F.R.D. 643, 671 n.25 (C.D. Cal. 2014) (food products have inherent nutritional value and, thus, are not worthless); *Brazil v. Dole Packaged Foods LLC*, 660 F. App’x 531, 534 (9th Cir. 2016) (full refund model inappropriate because some benefits were conferred); *In re Tobacco Cases II*, 240 Cal. App. 4th 779, 802 (2015) (full refund damages only proper where product confers no benefit on consumers); *In re Pom Wonderful LLC*, 2014 WL 1225184, at *3 (C.D. Cal. Mar. 25, 2014) (because plaintiffs received some benefit from the product (regardless of the benefits they sought) a full refund was inappropriate).

Nor can plaintiffs plausibly allege that they did not receive the benefit of the bargain of their purchase as courts in California and elsewhere have routinely rejected the claim that trace amounts of substances (including heavy metals) in consumer products negate the value of the

1 consumer's purchase. In *Boysen v. Walgreen Co.*, 2012 WL 2953069, at *4 (N.D. Cal. July 19,
 2 2012), the court found that plaintiffs lacked standing to bring a claim against a company for
 3 failure to disclose that its juice product contained lead. *Id.* at *1, 7. The plaintiffs admitted that
 4 the levels of lead in the juice were below FDA limits and that no plaintiff alleged physical harm.
 5 *Id.* at *1-2. Instead, plaintiffs argued that they had been injured in fact because they would not
 6 have bought the juice if they had known it contained any amount of lead. *Id.* The court rejected
 7 this theory of injury because, without any allegation that the juice tended to cause actual physical
 8 harm, plaintiffs had received the benefit of the bargain and thus had not alleged how purchasing
 9 the juice had injured them. *Id.* at *7; *see also Koronthaly v. L'Oreal USA, Inc.*, 2008 WL
 10 2938045, at *4-5 (D.N.J. July 29, 2008), *aff'd*, 374 F. App'x 257 (3d Cir. 2010) (plaintiff lacked
 11 standing to bring suit against lipstick manufacturer where trace amounts of lead in lipstick did
 12 not exceed FDA standards); *Moreno v. Vi-Jon, Inc.*, 2021 WL 807683 (S.D. Cal. March 3, 2021)
 13 (no injury where plaintiff did not allege that he purchased or used hand sanitizer to prevent any
 14 of the diseases or viruses the hand sanitizer purportedly failed to protect against, or that he
 15 contracted any of those diseases or viruses); *Doss v. Gen. Mills, Inc.*, 816 F. App'x 312, 314
 16 (11th Cir. 2020) (no economic injury because where plaintiffs alleged "ultra-low levels of
 17 glyphosate . . . may be harmful to human health"); *Green v. PepsiCo, Inc.*, 2019 WL 8810364, at
 18 *1, 3 (S.D. Fla. Apr. 12, 2019) (dismissing case because plaintiff failed to allege an injury in fact
 19 based on her purchase of Quaker Oats that allegedly contained trace amounts of residual
 20 glyphosate); *see also McGee*, 982 F.3d at 706 (plaintiff's assumption that food product
 21 containing trans fat contained only safe and healthy ingredients was not part of the bargain).

22 Nor can plaintiffs allege that they satisfy Article III based on a theory that they paid a
 23 price premium given that, according to the FACC, *all* baby food potentially contains trace
 24 amounts of heavy metals, making the presence of heavy metals irrelevant to pricing. FDA also
 25 confirms this point when it states that the alleged contaminants are omnipresent in the
 26 environment, and are inescapable, including for parents who opt to make their own foods.⁷

27 _____
 28 ⁷ Plaintiffs' assertion that several baby food products have paid to receive an endorsement from a
 for-profit third-party (the Clean Label Project's Purity Award) does not help them for several

1 Plaintiffs also confirm as much when they seek (in the prayer for relief) restitution of the *total*
 2 purchase price, not a price premium.

3 Plaintiffs cannot and do not allege they have been harmed by any of the products they
 4 purchased. The mere *possibility* that *some* products contained *some* levels of heavy metals which
 5 *could* cause harm under *certain* circumstances is, as a matter of law, insufficient to confer Article
 6 III standing.

7 **2. Plaintiffs Lack Standing To Seek Injunctive Relief**

8 Plaintiffs also lack Article III standing to pursue injunctive relief because they do not
 9 make the required allegation of a likelihood of suffering imminent and irreparable injury in the
 10 future without an injunction. *Davidson v. Kimberly-Clark Corp.*, 889 F.3d 956, 966-72 (9th Cir.
 11 2018); *see also Stover v. Experian Holdings, Inc.*, 978 F.3d 1082, 1087 (9th Cir. 2020)
 12 (*Davidson* requires a plaintiff to plausibly allege a desire to purchase the product in the future).
 13 Plaintiffs must demonstrate “a sufficient likelihood that [they] will *again* be wronged in a *similar*
 14 way,” but they fail to make those allegations. *City of L.A. v. Lyons*, 461 U.S. 95, 111 (1983)
 15 (emphasis added).

16 As the FACC readily and repeatedly acknowledges, plaintiffs are now fully aware that
 17 heavy metals are ubiquitous in the environment and that it is not possible to eliminate heavy
 18 metals in the food supply, including specifically in packaged baby food. Nevertheless, plaintiffs
 19 allege that they would be willing to purchase the products again in the future if they could be
 20 certain that they “do not contain heavy metals.” FACC ¶¶ 30, 33, 36, 39, 42, 45, 48, 51, 53, 56.
 21 But that doesn’t work. Plaintiffs are conclusively aware of the pervasiveness of heavy metals and
 22 cannot ignore the avalanche of allegations in the FACC making that crystal clear. “[W]here a

23 reasons, including that per plaintiffs’ allegations, the Clean Label Project “presents its Purity
 24 Award to companies with products with the *lowest* [not zero] levels of the contaminants when
 25 compared to other products in a given category.” FACC ¶ 150 (emphasis added). This does not
 26 mean that products endorsed by the Clean Label Project (for a fee) are free from, or have no
 27 material risk of containing, the alleged contaminants, and thus, according to plaintiffs’ own
 28 theory the products would still be deceptively marketed and sold. It is also worth noting that the
 award is not focused solely on measurement of the substances challenged in the FACC, but
 includes an analysis of other substances such as pesticide residues and plasticizers. *See*
<https://cleanlabelproject.org/purity-award/methodology/>.

1 plaintiff learns information during litigation that enables her to evaluate product claims and make
 2 appropriate purchasing decisions going forward, an injunction would serve no meaningful
 3 purpose as to that plaintiff.” *Jackson v. Gen. Mills, Inc.*, 2020 WL 5106652, at *5 (S.D. Cal.
 4 Aug. 28, 2020).

5 Moreover, plaintiffs’ assertion they “may” purchase the products again in the future if
 6 they could be certain that they do not contain heavy metals is too vague and uncertain to
 7 establish a likelihood of imminent harm. Plaintiffs do not allege that they are in a position to buy
 8 baby food again (e.g., that they are caretakers for infants or young children today or that
 9 someone in their household eats baby food), much less that that they have a concrete plan to
 10 purchase baby food and would be harmed without a disclaimer of facts they already know. *See*
 11 *Lanovaz v. Twinings N. Am., Inc.*, 726 F. App’x 590, 591 (9th Cir. 2018) (holding that the
 12 plaintiffs “would ‘consider buying’” allegations insufficient because profession of a “some day”
 13 intention does not support a finding of actual or imminent injury (quotation marks and citation
 14 omitted)); *Joslin v. Clif Bar & Co.*, 2019 WL 5690632, at *4 (N.D. Cal. Aug. 26, 2019) (no
 15 actual or imminent injury where plaintiffs alleged defendant’s product did not contain real white
 16 chocolate and they “do not want products that do not contain real white chocolate”).

17 Accordingly, plaintiffs cannot establish a likelihood of future harm sufficient to confer
 18 standing to sue for injunctive relief because the requested disclaimer of the potential presence of
 19 heavy metals in food would serve no purpose for them. *See Cimoli v. Alacer Corp.*, --- F. Supp.
 20 3d ----, 2021 WL 2711770, at *7 (N.D. Cal. July 1, 2021); *Rahman v. Mott’s LLP*, 2018 WL
 21 4585024, at *3 (N.D. Cal. Sept. 25, 2018).

22 **B. Plaintiffs’ Claims Should Be Dismissed As Preempted**

23 Separate from a failure of Article III standing, plaintiffs’ claims are preempted as
 24 conflicting with FDA’s considered judgment about the safety and labeling of baby food.
 25 Plaintiffs’ claims—and the underlying relief sought (mandatory food labeling or injunctions
 26 prohibiting the sale of baby food)—directly conflict with FDA’s role under federal law to
 27 establish a uniform, national policy for food safety, including regulation of heavy metals in the
 28 food supply. Under the Supremacy Clause, conflicts that arise between state and federal law

1 must, of course, be resolved in favor of federal law. *See* U.S. CONST. art. VI, cl. 2 (“[T]he Laws
2 of the United States . . . shall be the supreme Law of the Land”); *Maryland v. Louisiana*, 451
3 U.S. 725, 746-47 (1981). Conflict preemption applies where state law “stands as an obstacle to
4 the accomplishment and execution of the full purposes and objectives of Congress.” *Ting v.*
5 *AT&T*, 319 F.3d 1126, 1136 (9th Cir. 2003) (internal quotation marks and citations omitted).
6 Obstacle preemption applies when the Court can “infer that Congress made ‘a considered
7 judgment’ or ‘a deliberate choice’ to preclude state regulation when a federal enactment clearly
8 struck a particular balance of interests that would be disturbed or impeded by state regulation.”
9 *Cohen v. Apple, Inc.* 497 F. Supp. 3d 769 (N.D. Cal. 2020) (citing *Arizona v. United States*, 567,
10 U.S. 387, 405 (2012) (imposing criminal penalties on aliens who sought unlawful employment
11 would interfere with Congress’ judgment not to impose such penalties).

12 Significantly, where a federal regulatory agency like FDA has regulated in an area of its
13 expertise pursuant to a legal mandate, state law may not be used to bar conduct the agency has
14 chosen to not prohibit. Otherwise, the threat of civil liability would erect an obstacle to the
15 accomplishment of the comprehensive and carefully calibrated federal regulatory program. *See*
16 *Geier v. Am. Honda Motor Co.*, 529 U.S. 861, 881-82 (2000) (federal law that required a
17 percentage of new cars to employ passive-restraint systems impliedly preempted state tort claims
18 that would have had effect of requiring auto manufacturers to install air bags in all new cars);
19 *Fid. Fed. Sav. & Loan Ass’n v. de la Cuesta*, 458 U.S. 141, 156 (1982) (conflict preemption
20 where state law limited availability of an option that federal agency thought appropriate to ensure
21 its overall regulatory objectives); *Backus v. Nestlé USA, Inc.*, 167 F. Supp. 3d 1068, 1071 (N.D.
22 Cal. 2016) (tort suit imposing liability for presence of ingredient in food would impose liability
23 for something federal law permitted); *Cohen*, 497 F. Supp. at 785-86 (conflict preemption where
24 state law claims could establish testing requirements and standards that conflicted with the
25 uniform standards and testing established by the FCC). Attempts to commandeer FDA’s role to
26 regulate food safety and food labeling under the guise of state consumer protection law, as
27 plaintiffs attempt here, are preempted because they conflict with federal law and supremacy.
28

1 *Farina v. Nokia Inc.*, 625 F.3d 97 (3d Cir. 2010), is instructive. Relevant to that case, the
2 Federal Communications Commission (“FCC”) issued regulations that set limits for
3 radiofrequency (“RF”) radiation from phones (the “SAR Guidelines”). *Id.* at 107. Plaintiff filed a
4 lawsuit against Nokia asserting claims for personal injury due to RF radiation that was SAR
5 Guidelines-compliant, asserting that the sale of cell phones that emitted such RF radiation
6 violated *state* law, even though in compliance with the FCC regulations. *Id.* at 105, 107-8. The
7 Third Circuit found that “although [plaintiff] disavows any challenge to the FCC’s RF standards
8 . . . , to succeed, *he necessarily must establish that cell phones abiding by the FCC’s SAR*
9 *guidelines are unsafe to operate without a headset*. In other words, [plaintiff] must show that
10 these standards are inadequate—that they are insufficiently protective of public health and
11 safety.” *Id.* at 122 (emphasis added). But the court held that “[a]s an agency engaged in
12 rulemaking, the FCC is well positioned to solicit expert opinions and marshal the scientific data
13 to ensure its standards both protect the public and provide for an efficient wireless network.
14 Allowing juries to perform their own risk-utility analysis and second-guess the FCC’s conclusion
15 would disrupt the expert balancing underlying the federal scheme.” *Id.* at 126. The court also
16 sought to avoid “state-law standards [that] could vary from state to state, eradicating the
17 uniformity necessary to regulating the wireless network.” *Id.* On this record, the Third Circuit
18 found that plaintiff’s claims were barred by conflict preemption. *Id.* at 133-34

19 Conflict preemption applies here for the same reasons. FDA pervasively regulates food
20 safety under a grant from Congress. FDA—singularly positioned to solicit expert opinions,
21 marshal the scientific data and harmonize stakeholder interests—has looked at and continues to
22 study the issues of heavy metals in foods and to regulate their presence in the food supply.
23 Contrary to plaintiffs’ demand in this lawsuit, FDA—as part of its historical study of heavy
24 metals—has *not* banned their presence in food entirely or found that baby food, much less any of
25 the products challenged in the lawsuit, is adulterated and cannot be sold. Nor, as part of its
26 renewed look at these same issues, has FDA provided any indication that action levels for heavy
27 metals, if adopted at all, will be set at 0, and it has not required any heavy metals labeling.
28 Instead, FDA has decided to take a holistic approach that balances several competing objectives,

1 and will set action levels as necessary to maintain the safety of the food supply. *See generally*
2 *Borders Decl.*, Ex. B. This is in accord with FDA’s historical approach, such as when FDA set
3 action levels for inorganic arsenic in rice cereals for infants, or allowable levels of inorganic
4 substances, including arsenic, cadmium, lead, and mercury, in bottled water. *See Borders Decl.*,
5 Ex. I; 21 C.F.R. § 165.110.

6 The same is true with plaintiffs’ request for label warnings or disclosures regarding the
7 presence of heavy metals. FDA is well aware of ubiquitous heavy metals, and has studied their
8 impact on food safety. The presence of heavy metals (and other unavoidable substances in food)
9 was specifically contemplated by the FDCA, which empowers FDA to set action levels and to
10 regulate adulterants to ensure food safety. 21 U.S.C. §§ 342, 346. Both Congress through the
11 FDCA, and FDA “in their deliberate judgment” and per their “deliberate choice” have not
12 required warning labels or disclosures about the presence of ubiquitous heavy metals on any
13 food, including baby food. In fact, in other contexts where it was suggested that FDA require
14 warnings to declare the presence of certain ingredients and substances, FDA has stated that it is
15 “unwilling to require a warning statement in the absence of clear evidence of a hazard. If the
16 agency were to require warnings for ingredients that only cause mild idiosyncratic responses, it
17 is concerned that it would overexpose consumers to warnings. As a result, consumers may
18 ignore, and become inattentive to, all such statements.” *Food Labeling; Declaration of*
19 *Ingredients*, 56 Fed. Reg. 28592-01, 28615 (Jun. 21, 1991). That concern is applicable here
20 because every food product would need to carry a disclaimer about the potential presence of
21 heavy metals, which would provide no benefit to consumers. Instead, FDA has made clear in the
22 Action Plan that it will address heavy metals in baby food by setting action levels if deemed
23 necessary and by working to reduce heavy metals in the food supply—not by requiring warning
24 labels or disclosures on baby food products.

25 Permitting plaintiffs and their counsel to act as FDA, under the guise of state law, to set
26 their own requirements and ban trace amounts (or the risk) of contaminants altogether or to find,
27 retroactively, that Plum baby food products should not have been sold or should have a warning
28 label, would “disrupt the expert balancing underlying the federal scheme.” *Farina*, 625 F. 3d at

1 126. A determination of what requirements, if any, should be mandated, and the action levels, if
 2 any, that should be set, is squarely for FDA to make. Otherwise, patchwork, contradicting court
 3 orders in different cases across the country would make it impossible for companies to comply.
 4 Accordingly, the conflict preemption doctrine requires dismissal of the FACC.

5 **C. Plaintiffs' Claims Fall Under FDA's Primary Jurisdiction**

6 At an absolute minimum, the case should be dismissed (or stayed) because its subject
 7 matter—the regulation of heavy metals and other contaminants in the U.S. supply of baby
 8 food—is to be left to the consideration, judgment, and determinations of FDA, the federal
 9 agency with jurisdiction over these issues, with the expertise and resources to handle them
 10 properly, and with an open formal docket to engage in rulemaking over them. Significantly,
 11 plaintiffs' claims raise numerous food regulatory issues that under the law require resolution by
 12 FDA, including the safety of baby food, permitted action levels of heavy metals, what testing and
 13 manufacturing processes should be required by manufacturers, and the proper labeling of baby
 14 food. *See generally* FACC; *see also Backus v. Gen. Mills, Inc.*, 122 F. Supp. 3d 909, 933–35
 15 (N.D. Cal. 2015). Indeed, plaintiffs specifically ask the Court to enjoin Plum from selling baby
 16 food that contains any level of heavy metals and/or unless full disclosure of the presence of
 17 heavy metals appears on the label. FACC, Prayer for Relief. These issues require a carefully
 18 calibrated national approach to food safety and labeling based on science and only after input
 19 from all stakeholders. These issues should not be decided in the first instance by the courts, in a
 20 consumer class action no less.

21 “Primary jurisdiction is a prudential doctrine that permits courts to determine ‘that an
 22 otherwise cognizable claim implicates technical and policy questions that should be addressed in
 23 the first instance by the agency with regulatory authority over the relevant industry rather than by
 24 the judicial branch.’” *Astiana v. Hain Celestial Grp., Inc.*, 783 F.3d 753, 760 (9th Cir. 2015)
 25 (citation omitted). “The primary jurisdiction doctrine allows courts to stay proceedings or to
 26 dismiss a complaint without prejudice pending the resolution of an issue within the special
 27 competence of an administrative agency.” *Clark v. Time Warner Cable*, 523 F.3d 1110, 1114
 28 (9th Cir.2008). The doctrine applies where, as here, “if a claim ‘requires resolution of an issue of

1 first impression, or of a particularly complicated issue that Congress has committed to a
2 regulatory agency” and when “protection of the integrity of a regulatory scheme dictates
3 preliminary resort to the agency which administers the scheme.” *Reese v. Odwalla, Inc.*, 30 F.
4 Supp. 3d 935, 940 (N.D. Cal. 2014).

5 Courts consider four factors in determining whether to apply the primary jurisdiction
6 doctrine: “(1) the need to resolve an issue that (2) has been placed by Congress within the
7 jurisdiction of an administrative body having regulatory authority (3) pursuant to a statute that
8 subjects an industry or activity to a comprehensive regulatory authority that (4) requires
9 expertise or uniformity in administration.” *Syntek Semiconductor Co. v. Microchip Tech.*, 307
10 F.3d 775, 781 (9th Cir. 2002) (amended); *accord Astiana*, 783 F.3d at 760. Applying these
11 factors, numerous courts have stayed or dismissed false advertising cases where the underlying
12 theory of deception is incompatible with FDA’s primary jurisdiction. *See, e.g., Backus v. Gen.*
13 *Mills, Inc.*, 122 F. Supp. 3d at 933–35; *Glass v. Glob. Widget, LLC*, 2020 WL 3174688, at *2
14 (E.D. Cal. June 15, 2020); *Colette v. CV Scis., Inc.*, 2020 WL 2739861, at *1 (C.D. Cal. May 22,
15 2020); *Tran v. Sioux Honey Ass’n*, 2017 WL 5587276, at *2 (C.D. Cal. Oct. 11, 2017); *Kane v.*
16 *Chobani, LLC*, 645 F. App’x 593, 594-95 (9th Cir. 2016).

17 Here, the *Syntek* factors are met because the regulation of heavy metals in food is an issue
18 that Congress has placed within the jurisdiction of FDA because issues surrounding
19 establishment of standards for food safety and labeling require uniformity in administration.

20 First, issues concerning the safety of baby food, permitted action levels of heavy metals,
21 what testing and manufacturing processes should be required, and the proper labeling of baby
22 food fall squarely within the heart of FDA’s jurisdiction and mission. FDA is working to
23 promulgate regulations and/or formal guidance resolving FDA’s view on these issues, which will
24 be dispositive of the issues raised in the FACC. Indeed, if plaintiffs seek to impose additional or
25 different requirements on Plum, their claims will almost assuredly be expressly preempted. *See*
26 21 U.S.C. § 343-1. At the very least, FDA’s rulemaking and/or final guidance will be highly
27 relevant to Plum’s compliance with law. *See, e.g., Rosillo v. Annie's Homegrown Inc.*, 2017 WL
28 5256345, at *3 (N.D. Cal. Oct. 17, 2017) (FDA guidance regarding the term “natural” is relevant

1 to a question of how a reasonable consumer would understand that term); *In re KIND LLC*
 2 *"Healthy & All Natural" Litig.*, 209 F. Supp. 3d 689, 696 (S.D.N.Y. 2016) (similar).

3 Next, there is no question that "the FDCA subjects the food industry to comprehensive
 4 regulation." *Backus v. Gen. Mills*, 122 F. Supp. 3d at 934. "Specifically, the FDCA requires the
 5 FDA to (i) ensure that 'foods are safe, wholesome, sanitary, and properly labeled,' (ii)
 6 promulgate regulations to enforce the provisions of the FDCA, and (iii) enforce its regulations
 7 through administrative proceedings." *Hawkins v. Advancepierre Foods, Inc.*, 2016 WL 6611099,
 8 at *3 (S.D. Cal. Nov. 8, 2016), *aff'd*, 733 F. App'x 906 (9th Cir. 2018). This includes vesting
 9 FDA with authority to promulgate standards of food quality, and to address the issues raised by
 10 this case, including through setting action levels for poisonous substances in food. 21 U.S.C. §§
 11 341, 346. Moreover, and as this Court recognized in *Reese*, food labeling is an issue over which
 12 Congress vested the FDA with comprehensive regulatory authority. 30 F. Supp. 3d at 941. It is
 13 thus no surprise that FDA fully recognized its formal role on the issues implicated by the
 14 complaint, confirming that it "has been actively working on this issue using a risk-based
 15 approach to prioritize and target the agency's efforts." Borders Decl., Ex. C at 1.

16 Finally, in its Action Plan, FDA is formally and currently working to determine how best
 17 to address trace amounts of heavy metals in baby foods and to set additional action levels, as
 18 needed. *Reese*, 30 F. Supp. 3d at 941 ("This determination is a matter that is not only within the
 19 expertise and authority of the agency, it is before the agency at this moment."). Unless and until
 20 FDA completes its work, the Court will not have a clear indication as to how FDA views baby
 21 food safety and labeling, and what other factors FDA will set for industry compliance, such as
 22 compliance periods or safe harbors.

23 It is particularly important to permit FDA to apply its expertise in the first instance
 24 because the "process of reducing levels of toxic elements in foods is complicated and
 25 multifaceted." Borders Decl., Ex. D at 3. As just one example, "[i]t is crucial to ensure that
 26 measures to limit toxic elements in foods do not have unintended consequences—like
 27 eliminating foods with significant nutritional benefits or reducing the presence of one toxic
 28 element while increasing another." *Id.* Moreover, the alleged contaminants "are present in the

1 environment and may enter the food supply through soil, water or air . . . currently they cannot
2 be completely avoided in the fruits, vegetables, or grains that are the basis for baby foods . . .
3 made by companies or by consumers who make their own foods.” Borders Decl., Ex. C at 1.
4 FDA is uniquely capable of taking into consideration food safety, the adequacy of the food
5 supply, and the fact that alleged contaminants are omnipresent in the environment, and reducing
6 all of that to feasible and achievable regulations and/or formal guidance. Borders Decl., Ex. E at
7 2 (“By taking into consideration issues related to feasibility and achievability, the FDA can help
8 to ensure equitable availability of safe and nutritious foods for all babies and young children.”).
9 “FDA has been actively working on this issue using a risk-based approach to prioritize and target
10 the agency’s efforts.” Borders Decl., Ex. C at 1. Where, as here, the issues posed by a case
11 implicate technical and policy considerations that should be addressed by FDA in the first
12 instance, courts should defer to FDA’s primary jurisdiction. *See Clark*, 523 F.3d at 1114--16
13 (applying primary jurisdiction doctrine where plaintiff’s claim “implicat[ed] technical and policy
14 questions that should be addressed in the first instance by the agency with regulatory authority
15 over the relevant industry rather than by the judicial branch”).

16 FDA is uniquely situated to draw on vast resources and scientific data to resolve the
17 questions raised by the FACC. FDA has confirmed that it will “work with federal partners,
18 academia, and other stakeholders to inform the development of action levels of lead, cadmium,
19 mercury, and arsenic in foods for babies and young children.” Borders Decl., Ex. D at 3.
20 Moreover, it will utilize an “iterative science-based approach for continual improvement and the
21 timeframe for completing action items in three phases.” Borders Decl., Ex. E at 2. FDA can draw
22 resources and pull data and information from various sources to which the Court and jurors do
23 not have access.

24 This all precisely fits with the courts’ recognition that “[w]hether a body of evidence
25 sufficiently demonstrates that a particular amount of a chemical substance poses a serious public
26 health risk is precisely the kind of expert question that agencies are better suited to answer than
27 courts or juries.” *Backus v. Gen. Mills*, 122 F. Supp. 3d at 934; *see also Tran*, 2017 WL
28 5587276, at *2 (“These assertions indicate that Tran’s contention that she was misled depends on

1 the harmful nature of glyphosate. Moreover, it is undisputed that no tolerance level has been set
 2 for glyphosate in honey and no labeling requirement exists with respect to glyphosate in honey
 3 either. The Court is thus unable to conclude whether the ‘Pure’ and ‘100% Pure’ labeling was
 4 misleading without guidance from the FDA on glyphosate’s toxicity.”).

5 Permitting courts to act prior to FDA completing its work on the Action Plan won’t just
 6 seriously disrupt the regulatory process and invade FDA’s jurisdiction, but it will also destroy
 7 national uniformity. Decisions issuing from the scores of putative class action lawsuits pending
 8 against baby food manufacturers in districts across the country will inevitably result in an
 9 unworkable patchwork of determinations regarding food safety and labeling requirements that
 10 vary by Court, by manufacturer and by product. Plum, for example, could be subjected to
 11 completely different requirements by this Court as opposed to the Court in New Jersey. Plum
 12 could also be subjected to different requirements from other baby food manufacturers based on
 13 decisions in their respective courts. That would also result in different labeling and standards
 14 between baby food products, Gerber subject to different standards from Plum, and both different
 15 from Beech-Nut. Thus, dismissing or “staying this action until the FDA offers guidance at the
 16 federal level would almost certainly help harmonize court rulings—an important consideration in
 17 view of the fact that ‘Congress [did] not want to allow states to impose disclosure requirements
 18 of their own on packaged food products, most of which are sold nationwide’ to avoid the need
 19 for ‘[m]anufacturers . . . to print 50 different labels.’” *In re KIND*, 209 F. Supp. 3d at 696
 20 (citation omitted).

21 **D. Plaintiffs Fail To Plausibly Allege Deception**

22 “Heavy metals are naturally occurring in soil and water,” and so “[f]ood crops,”
 23 including crops like carrots and sweet potatoes used by Plum in the manufacture of its baby food
 24 products, “uptake these metals naturally.” Borders Decl., Ex. A at 2. The levels of these elements
 25 in foods depend on many factors, including the levels in the air, water, and soil used to grow the
 26 crops, and the type of crop and how much uptake there is from the environment. Borders Decl.,
 27 Ex. B at 1-2. “Because these elements occur in the environment, currently they cannot be
 28 completely avoided in the fruits, vegetables, or grains that are the basis for baby foods, juices,

1 and infant cereals made by companies or by consumers who make their own foods.” Borders
 2 Decl. Ex. C at 1. “They also cannot be completely avoided by using organic farming practices.”
 3 *Id.* Accordingly, “parents can’t shop their way out of these exposures by choosing organic foods
 4 or by switching from store-bought brands to homemade purees.” Borders Decl. Ex. A at 2.

5 The foundation of plaintiffs’ false advertising claims is the allegation that Plum
 6 “misleadingly” failed to disclose that “[h]eavy [m]etals, perchlorate, and/or other undesirable
 7 toxins or containments” may be present (or that there is a material risk that they may be present)
 8 in Plum’s baby food. *See, e.g.*, FACC ¶ 11; 165-184. Plaintiffs allege they would not have
 9 purchased Plum’s baby food (or, assumedly, any baby food) if they had known that heavy metals
 10 were present or potentially present in baby food as a result of ingredients like water, rice, sweet
 11 potatoes or carrots. *Id.* ¶¶ 30, 33, 36, 39, 42, 45, 48, 51, 53, 56. This theory of deception is
 12 implausible for two independent reasons.

13 *First*, plaintiffs’ alleged ignorance of the presence of ubiquitous heavy metals in food is
 14 implausible as a matter of law, since it is directly contradicted by the allegations in the FACC.
 15 The FACC readily acknowledges the existence of widespread, general public knowledge,
 16 information, and research regarding heavy metals in food and baby food, as well as specific
 17 disclosures regarding heavy metals on Plum’s website. Specifically, plaintiffs reference and cite
 18 the many “reports and articles that identified the presence of Heavy Metals, perchlorate, and/or
 19 other undesirable toxins or contaminants in their Baby Foods” going back years. Additionally,
 20 those same reports make it clear that it was publicly known that the same heavy metals that exist
 21 in packaged food bought in the market exist in food grown in peoples’ home gardens. FACC
 22 ¶ 195. For example, the well-publicized data points relied on in the FACC include:⁸

24 ⁸ In addition to this list, the FACC cites to scientific articles and FDA pronouncements stating
 25 the alleged harms of exposure to heavy metals going back many years. FACC at ¶¶ 101, nn. 31-
 26 32; 106 (“the knowledge of the risks associated with exposure to heavy metals is not a new
 27 phenomenon”); 109, n.40; 122, nn.54-55; 141, n.69; 156 & n.82 (“as a result of public health
 28 efforts, exposure to lead has consistently and notably decreased over the past 40 years. These
 efforts include increasing awareness of the dangers of even low levels of lead exposure to young
 children.”); 163-164.

- 1 • In 2011, Consumer Reports published an article entitled “Consumer Reports tests
2 juices for arsenic and lead,” which noted the presence of arsenic and lead in apple
3 and grape juice, which a “poll of parents confirms are a mainstay of many
4 children’s diets.” Borders Decl., Ex. J (cited in Borders Decl., Ex. A at 17).
- 5 • In 2017, the Environmental Defense Fund (“EDF”) released a report entitled
6 “Lead in food: A hidden health threat,” which claimed that 20% of 2,164 baby
7 food samples tested by the FDA from 2003 to 2013 contained lead, and went on
8 to list the most common sources of lead including various fruit juices, sweet
9 potatoes, carrots, teething biscuits and cookies. Borders Decl., Ex. G.
- 10 • In 2018, Consumer Reports published an article entitled “Heavy Metals in Baby
11 Food: What You Need to Know.” FACC ¶ 195, n.97; Borders Decl., Ex. H. In
12 this article, Consumer Reports analyzed baby and toddler foods for arsenic, lead,
13 cadmium, and mercury. Borders Decl., Ex. H. Consumer Reports also purportedly
14 sent its testing results to different companies that then did their own follow-up
15 investigation, with at least one company responding that it was “reviewing our
16 protocols for further improvement.” *Id.* at 12.
- 17 • In 2019, the University of Miami, the Clean Label Project, and Ellipse Analytics
18 “published an article describing their study on lead and cadmium in baby food
19 products.” FACC at ¶ 195.
- 20 • Also in 2019, in a source cited frequently in the FACC, Healthy Babies Bright
21 Futures (“HBBF”) published a report regarding the presence of heavy metals in
22 baby food products. FACC ¶ 10 n.5; Borders Decl., Ex. A. In this report, HBBF
23 noted that “[a] number of baby food companies are setting *their own* standards in
24 the absence of enforceable federal limits or guidance” and accordingly, “packaged
25 baby foods may be increasingly likely to have *lower amounts* of heavy metals
26 than homemade varieties.” Borders Decl., Ex. A at 3 (emphasis added). HBBF
27 claimed that its report “demonstrat[ed] that tests on over 150 foods . . . found that
28 95% of the products tested had detectable levels of heavy metals.” *Id.*

1 Similarly, plaintiffs admit that Plum published on its website a set of “FAQs” in which
 2 Plum states “Heavy metals are present throughout the environment, including soil and water.
 3 Whether you are growing your own produce in your backyard, buying fresh produce from a
 4 farmer’s market or purchasing a product in the supermarket, these substances will be present in
 5 the food to some extent.” *See* FACC ¶¶ 88; 82. Indeed, plaintiffs concede, “organic products are
 6 just as likely to contain Heavy Metals as non-organic products.” *Id.* at ¶ 117. By these
 7 allegations, plaintiffs acknowledge that consumers are aware of the realities of food production
 8 and know that food products may contain trace residues of heavy metals, herbicides, and
 9 pesticides. *See, e.g.*, FACC ¶¶ 10 n.5; 82; 88; 94-138; 141 n.69; 150-156 & n.82; 163-167; 195.

10 In the Ninth Circuit, these allegations are dispositive because plaintiffs in false
 11 advertising cases are held to the common knowledge, experience, and sense that the reasonable
 12 consumer brings to the shopping process. *See Moore v. Trader Joe's Co.*, 4 F.4th 874, 882 (9th
 13 Cir. 2021) (dismissal of complaint affirmed because reasonable consumer would not be deceived
 14 by ambiguous label as alleged; “court [should] consider[] other [non-product-label] information
 15 readily available to the consumer that could easily resolve the alleged ambiguity”); *McGee*, 982
 16 F.3d at 707-708 (consumers just know that trans fat comes from partially hydrogenated oil and
 17 that trans fat is not healthy). Accordingly, it is not plausible that plaintiffs were blithely ignorant
 18 of the possibility that trace amounts of heavy metals or other alleged contaminants are in baby
 19 food absent a specific label disclosure. FACC ¶ 30 (emphasis added); *see also* ¶¶ 33, 36, 39, 42,
 20 45, 48, 51, 53, 56.

21 *Second*, courts routinely find that because trace contaminants are ubiquitous in the food
 22 supply, their mere presence (or possibility of their presence) does not state a claim because it is
 23 “not likely to affect consumers’ decisions in purchasing the product and is thus not material.”
 24 *Parks v. Ainsworth Pet Nutrition, LLC*, 377 F. Supp. 3d 241, 248 (S.D.N.Y. 2020); *see also*
 25 *Parks v. Ainsworth Pet Nutrition, LLC*, 2020 WL 832863, at *1 (S.D.N.Y. Feb. 20, 2020) (“The
 26 level of glyphosate in the tested Products is negligible and significantly lower than the FDA’s
 27 limit, which supports a finding that the Products’ glyphosate residue is not likely to affect
 28 consumer choice”); *Herrington*, 2010 WL 3448531, at *8 (dismissing omission claims regarding

1 trace amounts of formaldehyde and dioxane for failure to allege facts showing that omissions
 2 were material to reasonable consumers); *In re Gen. Mills Glyphosate Litig.*, 2017 WL 2983877,
 3 at *5 (D. Minn. July 12, 2017) (not plausible that a reasonable consumer would be deceived by
 4 trace glyphosate in food product); *Axon v. Citrus World, Inc.*, 354 F. Supp. 3d 170, 183
 5 (E.D.N.Y. 2018), *aff'd sub nom. Axon v. Florida's Nat. Growers, Inc.*, 813 F. App'x 701 (2d
 6 Cir. 2020) ("Given the widespread use of herbicides, the court finds it 'implausible that a
 7 reasonable consumer would believe that a product labeled ['Florida's Natural'] could not contain
 8 a trace amount of glyphosate that is far below the amount' deemed tolerable by the FDA.")
 9 (alteration in original) (citation omitted) (affirming district court's grant of a motion to dismiss);
 10 *Tran v. Sioux Honey Ass'n*, 2020 WL 3989444, at *4-5 (C.D. Cal. July 13, 2020) (no evidence
 11 reasonable consumers are deceived by the presence of trace amounts of glyphosate); *Gibson v.*
 12 *Quaker Oats Co.*, 2017 WL 3508724, at *4 (N.D. Ill. Aug. 14, 2017) (dismissing claims based
 13 on the alleged presence of glyphosate as preempted); *Yu v. Dr Pepper Snapple Grp.*, 2019 WL
 14 2515919, at *3 (N.D. Cal. June 18, 2019) (reasonable consumer would not understand "Natural"
 15 to mean the utter absence of residual pesticides, which are well below allowable tolerances).

16 FDA has confirmed that the levels of heavy metals contained in food are safe and that
 17 baby food, including the Plum baby food challenged here, is not adulterated. Borders Decl., Ex.
 18 D at 2; Ex. E at 4. This record, combined with the above holdings, compels two dispositive
 19 conclusions: (i) consumers know and understand that trace amounts of heavy metals and other
 20 alleged contaminants in food products are ubiquitous, *and* (ii) absent allegations that the levels
 21 contained in the challenged products exceed FDA levels or render the products adulterated, the
 22 mere presence of heavy metals is not material to reasonable consumers. Accordingly, plaintiffs'
 23 consumer deception claims should be dismissed on this independent basis.

24 **E. Plaintiffs' Breach Of Implied Warranty Claim Fails**

25 A breach of the implied warranty of merchantability requires that the challenged product
 26 is defective or not fit for the ordinary purpose for which the product is used. *See, e.g., Hauter v.*
 27 *Zogarts*, 14 Cal. 3d 104, 117-18 (1975); *Barreto v. Westbrae Nat.*, 2021 WL 76331, at *7
 28 (S.D.N.Y. Jan. 7, 2021); *Sportmart, Inc. v. Spirit Mfg.*, 1999 WL 350662, at *3 (N.D. Ill. May

17, 1999) (“Under the implied warranty of merchantability, goods must be ‘fit for the ordinary purposes for which such goods are used.’”); *Dennis v. Whirlpool Corp.*, 2007 WL 9701826, at *6 (S.D. Fla. Mar. 13, 2007) (similar); *Daigle v. Ford Motor Co.*, 713 F. Supp. 2d 822, 826 (D. Minn. 2010) (similar). The implied warranty does not impose a general requirement that goods precisely fulfill the expectation of the buyer. *Stearns v. Select Comfort Retail Corp.*, 2009 WL 1635931, at *8 (N.D. Cal. June 5, 2009). “[T]here must be a fundamental defect that renders the product unfit for its ordinary purpose.” *Id.* A food product is fit for its ordinary purpose if it is fit for consumption. *See, e.g., Thomas v. Costco Wholesale Corp.*, 2014 WL 5872808, at * 3 (N.D. Cal. Nov. 12, 2014) (for food, an implied warranty claim requires that the product was unsafe to consume); *Barreto*, 2021 WL 76331, at *7.

Plaintiffs have not alleged that Plum’s products contain heavy metals in amounts rendering them unsafe for human consumption—the ordinary purpose of baby food. In fact, FDA has expressly stated that packaged baby food is safe to consume, is not adulterated, and that parents should not throw away baby food products or cease feeding them to their children. Because plaintiffs failed to allege that the products are unfit for consumption, the claims must be dismissed. *See Viggiano v. Hansen Nat. Corp.*, 944 F. Supp. 2d 877, 896 (C.D. Cal. 2013); *Bohac v. Gen. Mills, Inc.*, 2014 WL 1266848, at *10 (N.D. Cal. Mar. 26, 2014).

F. Request For Judicial Notice

Plum respectfully requests that the Court take judicial notice of the concurrently-filed Exhibits to the Borders Declaration pursuant to Federal Rule of Evidence 201.

Exhibits A, G through H, and K of the Borders Declaration are judicially noticeable because they are incorporated into the FACC by reference. Plaintiffs cite and rely on Exhibit A in support of their allegations of misrepresentation, which in turn cites to Exhibit K at p.17. *See* FACC at ¶¶ 10, 97, 105, 108, 121, 125, 129, 131, 135, 139, 159, 195, 260. Exhibit H is cited at ¶ 195 n.97 and plaintiffs rely on it in support of their breach of implied warranty claim. Finally, Exhibit G is cited in Exhibit 1 to the FACC, on which plaintiffs heavily rely. FACC at Ex. 1 at p. 22, n.50. The case law is clear that courts may take into consideration documents referenced or relied on in the complaint under the “incorporation by reference” doctrine. *Busey v. P.W.*

1 *Supermarkets, Inc.*, 368 F. Supp. 2d 1045, 1049 (N.D. Cal. 2005) (“[T]he court may consider a
 2 document not attached to the complaint if the complaint specifically refers to it and its
 3 authenticity is not questioned.”).

4 Exhibits B through F and I through J of the Borders Declaration consist of documents
 5 published by FDA. They are subject to judicial notice because they “can be accurately and
 6 readily determined from sources whose accuracy cannot reasonably be questioned,” and are a
 7 matter of public record. Fed. R. Evid. 201(b). Courts routinely take judicial notice of public
 8 records of government agencies, including public comments and other documents from FDA.
 9 *See Riva v. Pepsico, Inc.*, 2015 WL 993350, at *9 n.6 (N.D. Cal. Mar. 4, 2015) (taking judicial
 10 notice of “an FDA publication and an FDA presentation that was accessed from the FDA’s
 11 website”); *Wilson v. Frito-Lay N. Am., Inc.*, 260 F. Supp. 3d 1202, 1207 (N.D. Cal. 2017)
 12 (“Courts routinely take judicial notice of similar FDA guidance documents, many of which also
 13 appear on FDA’s public website”).

14 **IV. CONCLUSION**

15 For the foregoing reasons, Plum respectfully requests that the first amended consolidated
 16 class action complaint be dismissed with prejudice, or, in the alternative, that the case be
 17 dismissed without prejudice or stayed in deference to FDA’s primary jurisdiction.

18 Dated: October 18, 2021

MAYER BROWN LLP
 Dale J. Giali
 Keri E. Borders

DECHERT LLP
 Hope Freiwald (admitted *pro hac vice*)
 Mark Cheffo (admitted *pro hac vice*)

by: /s/ Keri E. Borders
 Keri E. Borders

Attorneys for Defendant
 PLUM, PBC